ClinicalTrials.gg
CompletedNCT03415854NABPLAGEMDUpdated May 12, 2026Results posted

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

A Phase 2 interventional study of Paricalcitol (Zemplar) in Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma and Pancreatic Adenocarcinoma, sponsored by HonorHealth Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by HonorHealth Research Institute · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 298 open to participants now, 471 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
827th of 1,574
34 · median 37
Started
2018
with 80 others
Phase 2
488 of 1,851
45 open now
Registered
1,121st of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 827th largest by enrollment of the 1,574 interventional ones that give a count, is one of 81 that started in 2018, is one of 488 in phase 2, and was the 1,121st registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

298 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

293 more — sign in →

All 298 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.

Read the detailed description

Pancreatic cancer continues to be a highly lethal disease with an overall 5 year survival of only 8%. Since 2004, the incidence of pancreatic cancer has been increasing by 1.5% per year and it is estimated that there will be 53,670 new cases diagnosed in the United States in 2017, with 43,090 expected deaths. Pancreatic cancer is the third most common cause of cancer-related deaths in both men and women, and the incidence is about equal in both sexes. Of all types of pancreatic cancers, pancreatic ductal adenocarcinoma (PDA) is by far the most common, representing 80% of cases. Due to lack of adequate screening techniques, greater than 80% of patients at the time of diagnosis present with unresectable, advanced disease. Standard treatment options for inoperable patients with locally advanced and metastatic PDA have been quite limited. Gemcitabine monotherapy, approved by the Food and Drug Administration (FDA) in 1996, demonstrated a median survival of 5.7 months, and has been the mainstay in treating patients with PDA. The first combination regimen to demonstrate any survival benefit compared with gemcitabine alone was gemcitabine plus erlotinib, with median survival of 6.24 months versus 5.91 months for single agent gemcitabine.

A meta-analysis of randomized trials by Heinemann and colleagues showed that patients with advanced pancreatic cancer and a good performance status may benefit from combination chemotherapy with gemcitabine plus a platinum agent or a fluoropyrimidine. Multiple combination regimens are being utilized.

Recently, the regimen of 5-fluorouracil/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) compared with gemcitabine demonstrated improvement in both progression-free survival (PFS, 6.4 vs. 3.3 months) and overall survival (OS, 11.1 vs. 6.8 months) for patients with a good performance status. FOLFIRINOX, however, is associated with substantial grade 3 and 4 toxicities, including diarrhea, nausea, vomiting, fatigue, neutropenia and febrile neutropenia, and cannot be given to patients >76 years of age or in some cases patients with head of the pancreas tumors. An international phase III trial comparing paclitaxel protein bound (now called paclitaxel protein bound) plus gemcitabine to gemcitabine single agent demonstrated a statistically significant improvement in OS (8.5 vs. 6.7 months) for advanced pancreatic cancer patients using the gemcitabine and paclitaxel protein bound over gemcitabine alone.

A recently completed phase Ib/II trial of the combination of paclitaxel protein bound plus gemcitabine plus cisplatin in previously untreated stage IV pancreatic adenocarcinoma patients was presented at the 2017 Gastrointestinal Cancer Symposium. In 24 patients with stage IV pancreatic cancer they reported 8.3% complete response (CR), 62.5% partial response (PR), 16.7% stable disease and 12.5% progressive disease. The rationale for adding cisplatin to paclitaxel protein bound and gemcitabine is that in a study of 1,029 patients whose pancreatic cancer tumors underwent molecular profiling, 57% of these tumors were negative for expression of the excision repair cross-complementation group 1 (ERCC1), indicating sensitivity to a platinum anti-tumor agent. In addition to the above, in our whole genome/transcriptome sequencing analysis, we found that abnormal repair pathways were a feature of all of the pancreatic cancers that were sequenced. Cisplatin prevents cellular deoxyribonucleic acid (DNA) repair by binding to and causing crosslinking of DNA, triggering apoptosis. Cisplatin has been used in other combination regimens to treat patients with PDA. For example, the cisplatin, epirubicin, 5-fluorouracil and gemcitabine (PEFG) regimen had an acceptable toxicity profile and was associated with a 24% partial response rate, 5 month PFS and 8.3 month OS as second line therapy.

Most recently, a study showed that Vitamin D can change the pancreatic tumor microenvironment from an immunologically suppressive (tumor promoting) one to an immunologically hostile one (e.g. decreased IL-6, decreased CXCL12 etc.). In addition, in the same study, the vitamin D ligand calcipotriol decreased production of collagen, decreased myeloid derived suppressor cells (MDSCs) and decreased regulatory T cells. Remarkably, in clinical practice, the vitamin D analogue paricalcitol was observed to reverse chemotherapy resistance. Two individuals with pancreatic adenocarcinoma who were receiving paclitaxel protein bound and gemcitabine based combination chemotherapy developed progressive disease which was reversed by the addition of paricalcitol.

Based upon these promising clinical and pre-clinical data we are initiating a clinical trial combining paclitaxel protein bound, gemcitabine, and cisplatin for patients with metastatic PDA. When these patients develop progressive disease the vitamin D analog paricalcitol will be added to the regimen. The treatment will continue until further disease progression.

03

Conditions studied

  • Pancreatic Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Adenocarcinoma
  • Pancreas Metastases
  • Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years of age; male or female.
  2. or cytologically confirmed pancreatic ductal adenocarcinoma.
  3. Capable of providing and complying with trial procedures including obtaining paired during therapy
  4. Performance Status (KPS) of ≥ 70%.
  5. ≥ 12 weeks.
  6. Measurable tumor lesions according to 1.1 criteria.
  7. Women must agree not to become pregnant (e.g. for at least 1 year, surgically sterile, or practicing adequate methods) for the duration of the study and until 90 days after last dose of study treatment. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. Both male and female patients of must agree to use a reliable method of birth control during the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients must have received no previous radiotherapy, surgery, chemotherapy or therapy for the treatment of disease. Prior treatments in the setting with gemcitabine and/or Fluorouracil (5-FU) or gemcitabine administered as a radiation sensitizer are allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present.
  2. Palliative surgery and/or radiation treatment less than 4 weeks prior to initiation of study treatment.
  3. Exposure to any investigational agent within 4 weeks prior to initiation of study treatment.
  4. Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
  5. History of other (except cured basal or squamous cell carcinoma, superficial bladder cancer, prostate cancer in active surveillance, or carcinoma in situ of the cervix) unless documented free of cancer for ≥2 years.
  6. Laboratory values: Screening serum creatinine >1.5 mg/dL; total > (); (ALT) and aspartate aminotransferase (AST) ≥ 2.5x ULN or ≥ 5.0×ULN if liver metastases are present; \<1,500/mm3, concentration \<100,000/mm3, hematocrit level \<27% for females or \<30% for males, or coagulation tests ( [PT], partial thromboplastin time [PTT], International Normalized Ratio [INR]) >1.5×ULN unless on anticoagulation agents.
  7. Current, serious, cardiac arrhythmias as determined by the investigator.
  8. History of infection.
  9. Active, clinically significant serious infection requiring treatment with antibiotics, antivirals or anti-fungals.
  10. Any condition that might interfere with the patient's participation in the study or in the evaluation of the study results.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Paricalcitol (Zemplar)

    Participants will be treated with the regimen according to the study protocol. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization and undergo imaging to determine response, if any.

    Drug: Paricalcitol (Zemplar)

Interventions

  • DrugParicalcitolStudies of ParicalcitolParicalcitol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    combination therapy

    Also known as: Cisplatin (Platinol), Paclitaxel Protein Bound (Abraxane), Gemcitabine (Gemzar)

06

What researchers measure

Primary outcomes

  1. Best Overall Response (BOR)

    Best overall response (BOR) is defined as the best tumor response recorded 9 weeks after treatment initiation Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1). Responses are categorized as: complete response (CR), disappearance of all target lesions; partial response (PR), ≥30% decrease in the sum of the longest diameter of target lesions; stable disease (SD), no change in target lesion size; and progressive disease (PD), ≥20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions. MRI completed every 3 cycles of treatment to determine if the tumor responded to treatment. A confirmatory positron emission tomography (PET) scan could be ordered to confirm CR.

    Time frame: From enrollment until the end of 3+ treatment cycles (each cycle is 21 days), up to 190 days.

  2. Progression-free Survival (PFS)

    Progression-free survival (PFS) is defined as the time from starting paricalcitol until disease progression. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a ≥20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From start of paricalcitol to disease progression, up to 7 months

  3. Overall Survival (OS)

    Overall survival (OS) is defined as the length of time that patients remained alive after starting paricalcitol treatment.

    Time frame: From start of paricalcitol through follow-up, up to 16.5 months

Secondary outcomes

  1. Serum Levels of Carbohydrate Antigen 19-9 (CA19-9)

    Carbohydrate antigen 19-9 (CA 19-9) is a validated serum biomarker for pancreatic cancer tumor burden used to monitor treatment response. Serum CA19-9 values were measured after each cycle of treatment to identify if they normalized over time. The median beta coefficient (slope of the regression line) among CA 19-9 expressing participants in a linear mixed effects model of log-transformed CA 19-9 is reported here. A positive beta coefficient is associated with increasing CA 19-9 levels over time (higher tumor burden; no treatment response), while a negative beta coefficient is associated with decreasing CA 19-9 levels over time (lower tumor burden; treatment response).

    Time frame: At the end of each treatment cycle (each cycle is 21 days), up to 30 weeks.

  2. Adverse Events Possibly Related to Paricalcitol

    The number of patients who experienced an adverse event (AE) determined to be possibly related to the study treatment of paricalcitol. Adverse events occurring were graded according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Grade refers to the severity of the AE and are given on a 1-5 scale, with each scale having unique clinical descriptions of severity for each AE based on this general guideline: * Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. * Grade 2: Moderate; minimal, local or noninvasive intervention indicated * Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling * Grade 4: Life-threatening consequences; urgent intervention indicated. * Grade 5: Death related to AE.

    Time frame: From enrollment through 30 days after last paricalcitol treatment, up to 16.5 months

07

Results

Posted May 12, 2026
Limitations and caveats
Limitations of this study include the small sample size, lack of dose escalation, and no placebo control group. Furthermore, exploratory analyses of tumor tissue samples and some circulating markers were unable to be completed due to impacts from the COVID-19 pandemic, limiting our ability to understand if there were any molecular or structural changes to the TME with paricalcitol treatment or systemic pathway impacts.

Participant flow

34 participants with metastatic PDAC were enrolled at 2 sites. 16 participants went on to commence paricalcitol upon attaining stable disease (SD) or progressive disease (PD) on first-line chemotherapy. Data from those 16 patients were analyzed for the purposes of this study.

Participant flow — Overall Study
MilestoneParicalcitol (Zemplar)
Started16
Completed14
Not completed2

Outcome measures

PrimaryBest Overall Response (BOR)

Best overall response (BOR) is defined as the best tumor response recorded 9 weeks after treatment initiation Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1). Responses are categorized as: complete response (CR), disappearance of all target lesions; partial response (PR), ≥30% decrease in the sum of the longest diameter of target lesions; stable disease (SD), no change in target lesion size; and progressive disease (PD), ≥20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions. MRI completed every 3 cycles of treatment to determine if the tumor responded to treatment. A confirmatory positron emission tomography (PET) scan could be ordered to confirm CR.

Time frame:
From enrollment until the end of 3+ treatment cycles (each cycle is 21 days), up to 190 days.
Reported as:
Count of participants · Participants
Best Overall Response (BOR)
ParticipantsParicalcitol (Zemplar)
Complete response (CR)0
Partial response (PR)0
Stable disease (SD)3
Progressive disease (PD)11
SecondarySerum Levels of Carbohydrate Antigen 19-9 (CA19-9)

Carbohydrate antigen 19-9 (CA 19-9) is a validated serum biomarker for pancreatic cancer tumor burden used to monitor treatment response. Serum CA19-9 values were measured after each cycle of treatment to identify if they normalized over time. The median beta coefficient (slope of the regression line) among CA 19-9 expressing participants in a linear mixed effects model of log-transformed CA 19-9 is reported here. A positive beta coefficient is associated with increasing CA 19-9 levels over time (higher tumor burden; no treatment response), while a negative beta coefficient is associated with decreasing CA 19-9 levels over time (lower tumor burden; treatment response).

Time frame:
At the end of each treatment cycle (each cycle is 21 days), up to 30 weeks.
Reported as:
Number · Beta coefficient
Serum Levels of Carbohydrate Antigen 19-9 (CA19-9)
Beta coefficientParicalcitol (Zemplar)
Serum Levels of Carbohydrate Antigen 19-9 (CA19-9)0.057 (0.042 to 0.072)
Statistical analysis
  • Paricalcitol (Zemplar) · Mixed Models Analysis · p = 0.001
SecondaryAdverse Events Possibly Related to Paricalcitol

The number of patients who experienced an adverse event (AE) determined to be possibly related to the study treatment of paricalcitol. Adverse events occurring were graded according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Grade refers to the severity of the AE and are given on a 1-5 scale, with each scale having unique clinical descriptions of severity for each AE based on this general guideline: * Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. * Grade 2: Moderate; minimal, local or noninvasive intervention indicated * Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling * Grade 4: Life-threatening consequences; urgent intervention indicated. * Grade 5: Death related to AE.

Time frame:
From enrollment through 30 days after last paricalcitol treatment, up to 16.5 months
Reported as:
Count of participants · Participants
Adverse Events Possibly Related to Paricalcitol
ParticipantsParicalcitol (Zemplar)
Anemia — Grade 1-20
Anemia — Grade 3-41
Anemia — Not Affected15
Diarrhea — Grade 1-21
Diarrhea — Grade 3-40
Diarrhea — Not Affected15
Vomiting — Grade 1-21
Vomiting — Grade 3-40
Vomiting — Not Affected15
Fatigue — Grade 1-21
Fatigue — Grade 3-40
Fatigue — Not Affected15
Arthralgia — Grade 1-21
Arthralgia — Grade 3-40
Arthralgia — Not Affected15
Back pain — Grade 1-21
Back pain — Grade 3-40
Back pain — Not Affected15
Lethargy — Grade 1-21
Lethargy — Grade 3-40
Lethargy — Not Affected15
Rash — Grade 1-21
Rash — Grade 3-40
Rash — Not Affected15
PrimaryProgression-free Survival (PFS)

Progression-free survival (PFS) is defined as the time from starting paricalcitol until disease progression. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a ≥20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
From start of paricalcitol to disease progression, up to 7 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsParicalcitol (Zemplar)
Progression-free Survival (PFS)1.6 (1.3 to 2.4)
PrimaryOverall Survival (OS)

Overall survival (OS) is defined as the length of time that patients remained alive after starting paricalcitol treatment.

Time frame:
From start of paricalcitol through follow-up, up to 16.5 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsParicalcitol (Zemplar)
Overall Survival (OS)4.8 (2.4 to 10.4)

Adverse events

Collected over From enrollment until 30 days after last dose of study drug, up to 16.5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paricalcitol (Zemplar)16/16 (100%)7/16 (43.8%)10/16 (62.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventParicalcitol (Zemplar)
FeverGeneral disorders2/16
DyspneaRespiratory, thoracic and mediastinal disorders1/16
Biliary tract infectionInfections and infestations1/16
PainGeneral disorders1/16
Tumor painGeneral disorders1/16
Platelet count decreasedInvestigations1/16
Pleural effusionRespiratory, thoracic and mediastinal disorders1/16
Abdominal painGastrointestinal disorders1/16
AscitesGastrointestinal disorders1/16
VomitingGastrointestinal disorders1/16
Most frequent other events
Showing 10 of 27
Most frequent other events
EventParicalcitol (Zemplar)
Abdominal painGastrointestinal disorders5/16
Peripheral sensory neuropathyNervous system disorders4/16
Urinary tract infectionInfections and infestations3/16
Neutrophil count decreasedInvestigations3/16
AnemiaBlood and lymphatic system disorders2/16
ConstipationGastrointestinal disorders2/16
DiarrheaGastrointestinal disorders2/16
Edema limbsGeneral disorders2/16
Platelet count decreasedInvestigations2/16
LethargyNervous system disorders2/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Paricalcitol (Zemplar)
Median60 (43.1 to 78.7)
Sex: Female, Male
Sex: Female, Male(Participants)Paricalcitol (Zemplar)
Female7
Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Paricalcitol (Zemplar)
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American3
White9
More than one race1
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Paricalcitol (Zemplar)
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Paricalcitol (Zemplar)
United States16
Karnofsky Performance Status (KPS)
Karnofsky Performance Status (KPS)(Participants)Paricalcitol (Zemplar)
80%3
90%6
100%7
08

Study locations

1 site
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — If the study site is a 'covered site' under the definitions of the Health Insurance Portability and Accounting Act (HIPAA), the Investigator will ensure that the patient consents to the use of data by HonorHealth and its designees for the purposes of regulatory submissions, study publications, and drug approval. Stand Up To Cancer (SU2C) will be notified of any outputs of the research such as guidelines, publications, presentation, changes in service delivery etc. prior to external submission or presentation. In any oral or written report or poster presentation of Results or otherwise relating to the Research, the support of Cancer Research UK (CRUK), SU2C and the Lustgarten foundation will be acknowledged, displaying the relevant logs where possible. Any publications resulting from research funded in whole or in part by the Grant must be cited as required per signed confidentiality agreements.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: To be determined

Access criteria: The Investigator and any other study personnel involved in this study shall not disclose, or use for any purposes (other than for the performance of this study), any data, records, or other information (hereinafter collectively "information") disclosed to the Investigator or other study personnel. Such information shall remain the confidential and proprietary property of HonorHealth, and shall be disclosed only to the Investigator or other designated study personnel. The obligation of non-disclosure shall not apply to the following: relevant disclosure to potential study participants for the purpose of obtaining informed consent; information after such time that it is or becomes publicly available through no fault of the Investigator or other study personnel; and, information after such time that it is disclosed to the Investigator by a third party entitled to disclose such information.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2023, 70 months.

Results were first posted in May 2026, 2 years 5 months after primary completion.

Of 325 non-industry phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's 70 months is above that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jan 30, 2018
StartActual
Jan 31, 2018
Primary completionActual
Dec 11, 2023
CompletionActual
Dec 11, 2023
Results first posted
May 12, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03415854
Lead sponsor
HonorHealth Research Institute
Collaborators
Barts Cancer Institute, Abramson Cancer Center at Penn Medicine, Salk Institute for Biological Studies, Mayo Clinic, Princeton University, Imaging Endpoints, Translational Genomics Research Institute, Stand Up To Cancer, Cancer Research UK, Lustgarten Foundation, University of California, San Diego
Responsible party
Sponsor
First posted
Jan 30, 2018
Start date
Jan 31, 2018
Primary completion
Dec 11, 2023
Completion
Dec 11, 2023
Results posted
May 12, 2026
Last update
May 12, 2026

Study contacts

Erkut Borazanci, MD
principal investigator · HonorHealth Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paricalcitol

Start the discussion